Market Anticipates Arrival of 13 New Obesity Drugs by 2029 due to Increased Demand

A recent report by Global Data has revealed that the pharmaceutical industry is preparing to release around 13 new weight-loss treatments in the United States over the next five years. This surge in product launches is a response to the growing demand for such solutions in the market. Starting in 2024, the number of obesity drug launches is expected to significantly increase, reaching a peak of four launches per year in 2027 and 2028.

In comparison, only three products were introduced between 2019 and 2023, according to the same research firm. The rising number of obesity cases in the U.S.

is a key driver behind this demand, with the World Health Organization projecting that by 2030, half of American adults will be classified as obese. This is a sharp increase from 42% in 2020 and just 31% in 1999. Sales of weight-loss medications have also seen a notable uptick, with Novo Nordisk's Wegovy and Eli Lilly's Zepbound generating a combined $9.

7 billion in global sales in 2023. Novo Nordisk, a major player in the weight-loss drug market, is predicted to release six new products in the next five years. Among them, CagriSema, a combination of semaglutide and cagrilintide, is anticipated to enter the market by the end of 2025 and achieve sales of $7.

4 billion by 2029. Eli Lilly, a key competitor to Novo Nordisk, is also advancing in the weight-loss field with two anti-obesity medications in Phase 3 trials - orforglipron and retatrutide. Additionally, Lilly has partnered with Innovent Biologics to develop an anti-obesity drug named mazdutide, which is currently being reviewed by Chinese regulators.

Numerous other drug candidates are in mid-stage development for obesity, including Viking Therapeutics' VK2735, Structure Therapeutics' GSBR-1290, and Altimmune's pemvidutide. Companies like Pfizer, Boehringer Ingelheim, and Amgen are also actively engaged in creating new weight-loss treatments. Although the weight-loss drug market is expected to become increasingly competitive in the years ahead, GlobalData remains optimistic that there will be sufficient demand to support multiple players in the industry.